THERAPEUTICS
Buflomedil reduced cardiovascular events in peripheral arterial disease
| The first 150 words of the full text of this article appear below. |
A Leizorovicz
Dr A Leizorovicz, Service de Pharmacologie Clinique, Lyon, France; al@upcl.univ-lyon1.fr
STUDY DESIGN
randomised placebo controlled trial (Limbs International Medicinal Buflomedil [LIMB]).
concealed.*
blinded (patients and outcome assessors).*
STUDY QUESTION
123 centres in the Czech Republic, France, Hungary, and Russia.
2078 patients who were 40–90 years of age (median age 61 y, 80% men) and had documented peripheral arterial obstructive disease (PAD) and an ankle-brachial index at rest >0.30 and
0.80. Exclusion criteria were ischaemic rest pain, ulceration or gangrene, iliac or common femoral artery stenosis or occlusion, arterial occlusion of embolic origin, Buerger disease or any non-atherosclerotic arterial disease of the lower limb, any factor confounding evaluation of PAD or effect of study treatment, myocardial infarction (MI) or stroke in the past 45 days, vascular or endovascular surgery in the past 45 days or planned within the next month, active cancer, short life expectancy, thrombophilia, pregnancy, or breast-feeding.
buflomedil (n = 1043)
University of Western Ontario, London, Ontario, Canada
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
